

1/5/1

DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

009230643

WPI Acc No: 1992-358063/ 199244

XRAM Acc No: C92-158964

Nitroglycerin, propellant gas-free spray prepns. - stored in container in which the steel parts are made of V4A series steels to inhibit nitroglycerin decomposition

Patent Assignee: MINNESOTA MINING & MFG CO (MINN)

Inventor: GRUEN C; ZERBE H

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DE 4112303	A	19921022	DE 4112303	A	19910415	199244 B

Priority Applications (No Type Date): DE 4112303 A 19910415

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
DE 4112303	A	7	A61K-009/12	

Abstract (Basic): DE 4112303 A

A nitroglycerine-contg. propellant gas free spray prepn. contg. 0.1-5 wt.% active ingredient, a solvent and opt. conventional pharmaceutical auxilliaries uses a special steel in the dosing device. The steel is (a) a CrNiMo steel contg. 16-28% Cr, 10-35% Ni and 2-7% Mo, opt. with the conventional content of Ti, Nb, N and/or Cu used in austenitic stainless steels; (b) a CrNiH steel contg. 17-19% Cr, 9.0-11.5% Ni and 0.12-0.20% H; (c) a CrNi steel contg. 24-26% Cr and 20-22% Ni; (d) a CrNiSi steel contg. ca. 18% Cr, ca 15% Ni and ca 4% Si; or (e) NiCrAlTi steel contg. 20-23% Cr, 32-35% Ni, 0.15-0.45% Al and Ti is at least 8 x % (C+H) is less than 0.60.

USE/ADVANTAGE - The spray prepns. can be used buccally in the treatment of Angina pectoris. The use of the special steels as the steel component (e.g. in the valve) of the dosing device gives better stability of the active ingredient. The decomposition of the nitro-glycerine which normally occurs in propellant gas free prepns. is inhibited by replacing the V2A-steels conventionally used with the special steels listed.

Dwg.0/1

Title Terms: NITROGLYCERIN; PROPELLANT; GAS; FREE; SPRAY; PREPARATION; STORAGE; CONTAINER; STEEL; PART; MADE; SERIES; STEEL; INHIBIT; NITROGLYCERIN; DECOMPOSE

Derwent Class: B07; M27

International Patent Class (Main): A61K-009/12

File Segment: CPI

US 5392767 A 19950228 US 90487895 A 19900306 199514
US 91789446 A 19911107

Priority Applications (No Type Date): DE 3907414 A 19890308

Cited Patents: 2.Jnl.Ref; FM 3500; FR 3500

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
-----------	------	--------	----------	--------------

EP 386700	A			Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE
EP 386700	B1	G 10	A61K-031/635	Designated States (Regional): AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DE 59000518	G		A61K-031/635	Based on patent EP 386700
ES 2052998	T3		A61K-031/635	Based on patent EP 386700
US 5392767	A	8	A61M-011/00	Cont of application US. 90487895
IL 93663	A		A61K-009/72	

Abstract (Basic): EP 386700 A

Allergen-induced nasal reactions are treated by atomisation of a soln. of a 'ground' diuretic (I) in the nostrils. (I) is furosemide of formula (Ia).

USE - (Ia) is already known as a diuretic and for control of asthma. It is now found to reduce significantly nasal obstruction, secretion and symptoms induced by specific allergens. (11pp Dwg.No.0/5)

Title Terms: TREAT; ALLERGEN; INDUCE; NASAL; REACT; DIURETIC; ATOMISE; PREFER; FUROSEMIDE; NOSTRIL

Derwent Class: B03

International Patent Class (Main): A61K-009/72; A61K-031/635; A61M-011/00

International Patent Class (Additional): A61K-031/63; C07D-307/14

File Segment: CPI